FDA Approves Nyvepria (pegfilgrastim-apgf), a Biosimilar to Neulasta
FDA Approves Nyvepria (pegfilgrastim-apgf), a Biosimilar to Neulasta Print this page NEW YORK–(BUSINESS WIRE)– June 11, 2020 — Pfizer Inc. (NYSE: PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) has approved Nyvepria (pegfilgrastim-apgf), a biosimilar to Neulasta® (pegfilgrastim).1 Nyvepria is indicated to decrease the incidence of infection, as manifested by febrile… Read More »